01 noviembre 2013

EUROPEAN HEART JOURNAL. Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice

Seung-Jung Park1,†,*, Jung-Min Ahn1,†, Gyung-Min Park1, Young-Rak Cho1, Jong-Young Lee1, Won-Jang Kim1, Seungbong Han2, Soo-Jin Kang1, Duk-Woo Park1, Seung-Whan Lee1, Young-Hak Kim1, Cheol Whan Lee1, Gary S. Mintz3 and Seong-Wook Park1

Aims We evaluated the impact of the routine use of fractional flow reserve (FFR) on the practice and outcomes of percutaneous coronary intervention (PCI).

01 septiembre 2012

JAMA. Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes

Charlotte Andersson, MD, PhD; Stig Lyngbæk, MD; Cu Dinh Nguyen, MD; Mia Nielsen, MB; Gunnar H. Gislason, MD, PhD; Lars Køber, MD, DSc; Christian Torp-Pedersen, MD, DSc

Context: Pharmacodynamic studies have shown that persistently high platelet reactivity is common in patients with diabetes in spite of clopidogrel treatment. Clinical trials have not convincingly demonstrated that clopidogrel benefits patients with diabetes as much patients without diabetes.

01 septiembre 2013

THE LANCET. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials

Giulio G Stefanini MD a †, Usman Baber MD b †, Prof Stephan Windecker MD a, Marie-Claude Morice MD v, Samantha Sartori PhD b, Prof Martin B Leon MD c, Prof Gregg W Stone MD c, Prof Patrick W Serruys MD q, William Wijns MD d, Giora Weisz MD c, Edoardo Camenzind MD e, Prof Philippe G Steg MD g, Peter C Smits MD h, David Kandzari MD j, Clemens Von Birgelen MD i, Søren Galatius MD k, Raban V Jeger MD f, Prof Takeshi Kimura MD l, Ghada Mikhail MD m, Dipti Itchhaporia MD r, Laxmi Mehta MD t, Rebecca Ortega MHA s, Hyo-Soo Kim MD n, Marco Valgimigli MD o, Prof Adnan Kastrati MD p, Alaide Chieffo MD u, Dr Prof Roxana Mehran MD b

Background: The safety and efficacy of drug-eluting stents (DES) in the treatment of coronary artery disease have been assessed in several randomised trials. However, none of these trials were powered to assess the safety and efficacy of DES in women because only a small proportion of recruited participants were women. We therefore investigated the safety and efficacy of DES in female patients during long-term follow-up.

01 octubre 2013

CIRCULATION. Ischemic Postconditioning During Primary Percutaneous Coronary Intervention. The Effects of Postconditioning on Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction (POST) Randomized Trial

Joo-Yong Hahn, MD*; Young Bin Song, MD*; Eun Kyoung Kim, MD; Cheol Woong Yu, MD; Jang-Whan Bae, MD; Woo-Young Chung, MD; Seung-Hyuk Choi, MD; Jin-Ho Choi, MD; Jang-Ho Bae, MD; Kyung Joo An, MD; Jong-Seon Park, MD; Ju Hyeon Oh, MD; Sang-Wook Kim, MD; Jin-Yong Hwang, MD; Jae Kean Ryu, MD; Hun Sik Park, MD; Do-Sun Lim, MD; Hyeon-Cheol Gwon, MD

Background—Ischemic postconditioning has been reported to reduce infarct size in patients with ST-segment–elevation myocardial infarction. However, cardioprotective effects of postconditioning have not been demonstrated in a large-scale trial.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery DiseaseThe EXECUTIVE Trial (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease)

Flavio Ribichini, MD∗; Michele Romano, MD†; Renato Rosiello, MD†; Luigi La Vecchia, MD‡; Ester Cabianca, MD‡; Giuseppe Caramanno, MD§; Diego Milazzo, MD§; Paolo Loschiavo, MD‖; Stefano Rigattieri, MD‖; Salvatore Musarò, MD¶; Bruno Pironi, MD¶; Antonio Fiscella, MD#; Francesco Amico, MD#; Ciro Indolfi, MD∗∗; Carmen Spaccarotella, MD∗∗; Antonio Bartorelli, MD††; Daniela Trabattoni, MD††; Francesco Della Rovere, MD‡‡; Andrea Rolandi, MD‡‡; Federico Beqaraj, MD§§; Riccardo Belli, MD§§; Pietro Sangiorgio, MD‖‖; Rosvaldo Villani, MD¶¶; Andrea Berni, MD##; Imad Sheiban, MD∗∗∗; Maria Josè Lopera Quijada, MSC†††; Barbara Cappi, MSC†††; Licia Ribaldi, BS†††; Corrado Vassanelli, MD∗

Objectives: This study sought to investigate the efficacy and performance of the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in the treatment of de novo coronary lesions in patients with 2- to 3-vessel multivessel coronary artery disease (MV-CAD).

01 octubre 2013

JAMA. Risk of Major Adverse Cardiac Events Following Noncardiac Surgery in Patients With Coronary Stents

Mary T. Hawn, MD, MPH; Laura A. Graham, MPH; Joshua S. Richman, MD, PhD; Kamal M. F. Itani, MD; William G. Henderson, PhD; Thomas M. Maddox, MD, MSc

Importance: Guidelines recommend delaying noncardiac surgery in patients after coronary stent procedures for 1 year after drug-eluting stents (DES) and for 6 weeks after bare metal stents (BMS). The evidence underlying these recommendations is limited and conflicting.

01 agosto 2013

THE LANCET. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

Dr Stephen D Wiviott MD a , Prof Harvey D White DSc b, Prof E Magnus Ohman MB c d, Prof Keith AA Fox MBChB e, Prof Paul W Armstrong MD f, Dorairaj Prabhakaran MD g, Gail Hafley MS c, Yuliya Lokhnygina PhD c, Prof William E Boden MD h, Prof Christian Hamm MD i, Peter Clemmensen MD j, Jose C Nicolau MD k, Alberto Menozzi MD l, Witold Ruzyllo MD m, Petr Widimsky MD n, Ali Oto MD o, Jose Leiva-Pons MD p, Gregory Pavlides MD q, Kenneth J Winters MD r, Matthew T Roe MD c d, Prof Deepak L Bhatt MD, MPH a s

Background: Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only. We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen.

01 noviembre 2013

CIRCULATION. Interplay Between Mitral Regurgitation and Transcatheter Aortic Valve Replacement With the CoreValve Revalving System. A Multicenter Registry

Francesco Bedogni, MD; Azeem Latib, MD; Federico De Marco, MD; Mauro Agnifili, MD; Jacopo Oreglia, MD; Samuele Pizzocri, MD; Roberto A. Latini, MD; Stefania Lanotte, MD; Anna Sonia Petronio, MD; Marco De Carlo, MD; Federica Ettori, MD; Claudia Fiorina, MD; Arnaldo Poli, MD; Silvia Cirri, MD; Stefano De Servi, MD; Angelo Ramondo, MD; Giuseppe Tarantini, MD; Antonio Marzocchi, MD; Rosario Fiorilli, MD; Silvio Klugmann; Gian Paolo Ussia, MD; Corrado Tamburino, MD; Francesco Maisano, MD; Nedy Brambilla, MD; Antonio Colombo, MD; Luca Testa, MD, PhD

Background—Little is known of the prognostic significance of mitral regurgitation (MR) on transcatheter aortic valve replacement (TAVR), the impact of TAVR on MR severity, and the variables associated with possible post-TAVR improvement in MR. We evaluated these issues in a multicenter registry of patients undergoing CoreValve Revalving System–TAVR.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease. The ABSORB Cohort A Trial

Yoshinobu Onuma, MD∗; Dariusz Dudek, MD†; Leif Thuesen, MD‡; Mark Webster, MB ChB‡; Koen Nieman, MD, PhD∗; Hector M. Garcia-Garcia, MD, PhD‖; John A. Ormiston, MB ChB¶; Patrick W. Serruys, MD, PhD∗

Objectives: This study sought to demonstrate the 5-year clinical and functional multislice computed tomography angiographic results after implantation of the fully resorbable everolimus-eluting scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California).

01 octubre 2013

JACC. Impact of Periprocedural Bleeding on Incidence of Contrast-Induced Acute Kidney Injury in Patients Treated With Percutaneous Coronary Intervention

Yohei Ohno, MD; Yuichiro Maekawa, MD; Hiroaki Miyata, PhD; Soushin Inoue, MD; Shiro Ishikawa, MD; Koichiro Sueyoshi, MD; Shigetaka Noma, MD; Akio Kawamura, MD; Shun Kohsaka, MD; Keiichi Fukuda, MD, PhD

Objectives This study sought to evaluate the association between contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention and severity of bleeding estimated from periprocedural hemoglobin (Hb) measurement.

01 septiembre 2013

JACC. Percutaneous Mitral Valve Interventions in the Real World. Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe

Francesco Maisano, MD; Olaf Franzen, MD; Stephan Baldus, MD; Ulrich Schäfer, MD; Jörg Hausleiter, MD; Christian Butter, MD; Gian Paolo Ussia, MD; Horst Sievert, MD; Gert Richardt, MD; Julian D. Widder, MD; Tiziano Moccetti, MD; Wolfgang Schillinger, MD

Objectives: The purpose of this article is to report early and mid-term outcomes of the ACCESS-EU study (ACCESS-Europe A Two-Phase Observational Study of the MitraClip System in Europe), a European prospective, multicenter, nonrandomized post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).

01 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis. 2-Year Results From a Pooled Analysis

Gert Richardt, MD; Matthias Leschke, MD; Mohamed Abdel-Wahab, MD; Ralph Toelg, MD; Mohamed El-Mawardy, MD; Patrick W. Serruys, MD, PhD; Sigmund Silber, MD, PhD; Stephan Windecker, MD; Jorge A. Belardi, MD; Franz-Josef Neumann, MD, PhD; Petr Widimsky, MD, DrSc

Objectives: This study sought to assess the clinical safety and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in patients with in-stent restenosis (ISR) from 2 large trials.

01 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)

George D. Dangas, MD; Patrick W. Serruys, MD, PhD; Dean J. Kereiakes, MD; James Hermiller, MD; Ali Rizvi, MD; William Newman, MD; Krishnankutty Sudhir, MD, PhD; Robert S. Smith, PhD; Sherry Cao, MS; Kleanthis Theodoropoulos, MD; Donald E. Cutlip, MD; Alexandra J. Lansky, MD; Gregg W. Stone, MD

Objectives This study sought to investigate whether the everolimus-eluting stent (EES) is superior to the paclitaxel-eluting stent (PES) with respect to long-term individual clinical outcomes.

01 septiembre 2013

JACC. Aortic Stenosis in the Elderly. Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study

Ruben L.J. Osnabrugge, MS; Darren Mylotte, MD; Stuart J. Head, MS; Nicolas M. Van Mieghem, MD; Vuyisile T. Nkomo, MD, MPH; Corinne M. LeReun, MS; Ad J.J.C. Bogers, MD, PhD; Nicolo Piazza, MD, PhD; A. Pieter Kappetein, MD, PhD

Objectives: The purpose of this study was to evaluate the prevalence of aortic stenosis (AS) in the elderly and to estimate the current and future number of candidates for transcatheter aortic valve replacement (TAVR).

01 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Kissing Balloon Inflation on the Main Vessel Stent Volume, Area, and Symmetry After Side-Branch Dilation in Patients With Coronary Bifurcation Lesions. A Serial Volumetric Intravascular Ultrasound Study

Shahid Rahman, MD; Tara Leesar; Mehmet Cilingiroglu, MD; Mohamed Effat, MD; Imran Arif, MD; Tarek Helmy, MD; Massoud A. Leesar, MD

Objectives: Intravascular ultrasound (IVUS) was performed to investigate the impact of kissing balloon inflation (KBI) on the main vessel (MV) stent volume, area, and symmetry after side-branch (SB) dilation in patients with coronary bifurcation lesions (CBL).